Bone Changes and Fracture Risk in Individuals Infected With HIV
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The life expectancy of individuals infected with HIV has improved greatly since the institution of combination antiretroviral therapy. However, many metabolic derangements have been discovered with long-term combination antiretroviral treatment, including lipodystrophy; insulin resistance; and, more recently, abnormal bone metabolism. It is well-documented that bone mineral density (BMD) in HIV-positive patients is lower compared with the expected BMD in non–HIV-positive patients. The underlying cause of lower BMD is unknown but is thought to be a multifactorial process. Conflicting evidence exists regarding the effect of antiretroviral exposure and duration of treatment, antiretroviral type, and cumulative HIV viral exposure on bone health. Here we review the bone changes that occur with HIV infection and treatment.
- Brown TT, Ruppe MD, Kassner R, et al.: Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 2004, 89:1200–1206. CrossRef
- Bruera D, Luna N, David DO, et al.: Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003, 17:1917–1923. CrossRef
- Mondy K, Yarasheski K, Powderly WG, et al.: Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus–infected individuals. Clin Infect Dis 2003, 36:482–490. CrossRef
- Nolan D, Upton R, McKinnon E, et al.: Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001, 15:1275–1280. CrossRef
- Tebas P, Powderly WG, Claxton S, et al.: Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000, 14:F63–F67. CrossRef
- Prior J, Burdge D, Maan E, et al.: Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int 2007, 18:1345–1353. CrossRef
- •• Triant VA, Brown TT, Lee H, Grinspoon SK: Fracture prevalence among human immunodeficiency virus (HIV)–infected versus non–HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008, 93:3499–3504. This study provides an estimate of fracture occurrence in HIV-infected individuals compared with non–HIV-infected individuals within a large US hospital database. Evidence from the study supports the notion that HIV-positive individuals are at increased risk of fracture. CrossRef
- Brown TT, Qaqish RB: Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006, 20:2165–2174. CrossRef
- Dubé MP, Qian D, Edmondson-Melancon H, et al.: Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002, 35:475–481. CrossRef
- Jones S, Restrepo D, Kasowitz A, et al.: Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int 2008, 19:913–918. CrossRef
- Brown TT, McComsey GA, King MS, et al.: Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009, 51:554–561. CrossRef
- Overton ET, Mondy K, Bush T, et al.: Factors associated with low bone mineral density in a large cohort of HIV-infected US adults: baseline results from the SUN study [abstract]. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25–28, 2007.
- Aukrust P, Haug CJ, Ueland T, et al.: Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999, 84:145–150. CrossRef
- Alsina M, Guise TA, Roodman GD: Cytokine regulation of bone cell differentiation. Vitam Horm 1996, 52:63–98. CrossRef
- Abbas S, Zhang YH, Clohisy JC, Abu-Amer Y: Tumor necrosis factor-alpha inhibits pre-osteoblast differentiation through its type-1 receptor. Cytokine 2003, 22:33–41. CrossRef
- Blair HC, Robinson LJ, Zaidi M. Osteoclast signalling pathways. Biochem Biophys Res Commun 2005, 328:728–738. CrossRef
- Kostenuik PJ, Shalhoub V: Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 2001, 7:613–635. CrossRef
- Nguyen L, Dewhirst FE, Hauschka PV, Stashenko P: Interleukin-1 beta stimulates bone resorption and inhibits bone formation in vivo. Lymphokine Cytokine Res 1991, 10:15–21.
- Panagakos FS, Hinojosa LP, Kumar S: Formation and mineralization of extracellular matrix secreted by an immortal human osteoblastic cell line: modulation by tumor necrosis factor-alpha. Inflammation 1994, 18:267–284. CrossRef
- Manolagas SC: Role of cytokines in bone resorption. Bone 1995, 17:63S–67S. CrossRef
- Roodman GD: Role of cytokines in the regulation of bone resorption. Calcif Tissue Int 1993, 53(Suppl 1):S94–S98. CrossRef
- Gibellini D, De Crignis E, Ponti C, et al.: HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol 2008, 80:1507–1514. CrossRef
- Fakruddin JM, Laurence J: HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 2003, 278:48251–48258. CrossRef
- Fakruddin JM, Laurence J: Interactions among human immunodeficiency virus (HIV)-1, interferon-gamma and receptor of activated NF-kappa B ligand (RANKL): implications for HIV pathogenesis. Clin Exp Immunol 2004, 137:538–545. CrossRef
- Fakruddin JM, Laurence J: HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 2005, 150:67–78. CrossRef
- Cotter EJ, Malizia AP, Chew N, et al.: HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses 2007, 23:1521–1530. CrossRef
- Cotter EJ, Ip HS, Powderly WG, Doran PP: Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation. BMC Musculoskelet Disord 2008, 9:33. CrossRef
- Grund B, Peng G, Gibert CL, et al.: Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009, 23:1519–1529. CrossRef
- Bolland MJ, Grey AB, Horne AM, et al.: Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Clin Endocrinol (Oxf) 2007, 67:270–275. CrossRef
- Dolan SE, Kanter JR, Grinspoon S: Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2006, 91:2938–2945. CrossRef
- Duvivier C, Kolta S, Assoumou L, et al.: Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009, 23:817–824. CrossRef
- Fakruddin JM, Yin M, Laurence J: Pathophysiologic correlates of RANKL deregulation in HIV infection and its therapy [abstract]. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005.
- Woodward CL, Hall AM, Williams IG, et al.: Tenofovir-associated renal and bone toxicity. HIV Med 2009, 10:482–487. CrossRef
- Purdy JB, Gafni RI, Reynolds JC, et al.: Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008, 152:582–584. CrossRef
- Martin A, Bloch M, Amin J, et al.: Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009, 49:1591–1601. CrossRef
- Pan G, Kilby M, McDonald JM: Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors. AIDS Res Hum Retroviruses 2006, 22:1131–1141. CrossRef
- Tebas P, Yarasheski K, Henry K, et al.: Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004, 20:589–594. CrossRef
- Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191–201. CrossRef
- Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, et al.: Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008, 24:1375–1382. CrossRef
- Rodrîguez M, Daniels B, Gunawardene S, Robbins GK: High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses 2009, 25:9–14. CrossRef
- Haug C, Muller F, Aukrust P, Froland SS: Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis 1994, 169:889–893.
- Haug CJ, Aukrust P, Haug E, et al.: Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 1998, 83:3832–3838. CrossRef
- Cozzolino M, Vidal M, Arcidiacono MV, et al.: HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003, 17:513–520. CrossRef
- Villamor E: A potential role for vitamin D on HIV infection? Nutr Rev 2006, 64:226–233. CrossRef
- Arnsten JH, Freeman R, Howard AA, et al.: Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007, 21:617–623. CrossRef
- Mondy K, Powderly WG, Claxton SA, et al.: Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005, 38:426–431. CrossRef
- Negredo E, Martinez-López E, Paredes R, et al.: Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS 2005, 19:343–345.
- Guaraldi G, Orlando G, Madeddu G, et al.: Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials 2004, 5:269–277. CrossRef
- • Huang J, Meixner L, Fernandez S, McCutchan JA: A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 2009, 23:51–57. This study highlights the beneficial effect of bisphosphonate therapy in HIV-positive individuals with loss of BMD who are at risk of fracture. CrossRef
- Bone Changes and Fracture Risk in Individuals Infected With HIV
Current Rheumatology Reports
Volume 12, Issue 3 , pp 163-169
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Industry Sectors